IBD 50's GeneDx, Down 39%, Was 'Priced For Perfection.' Here's What It Missed.
In This Article:
Investors hammered GeneDx stock on Wednesday after the diagnostics company beat first-quarter expectations — but not by enough.
Terms and Privacy Policy